CellCarta Adds Tempus to Companion Diagnostics Lab Network
CellCarta has added Tempus as the second commercial laboratory partner in its CDx Commercialization Lab Network, the company announced in a press release.
The agreement adds Tempus to a network built to support oncology companion diagnostics for biopharma sponsors. CellCarta said it will develop and validate the companion diagnostic, generate analytical and clinical evidence, support regulatory submissions, and perform centralized immunohistochemistry and tissue testing.
Through Tempus Hub, healthcare providers can order tests, sample testing is routed to CellCarta, and results are sent back to ordering providers. Tempus joins Sonic Healthcare USA as the second member of the network.
CellCarta said the network is part of its CDx Accelerator Model, which covers four stages: Build, Validate, Launch, and Transfer. After approval, CellCarta activates commercial laboratory partners to support launch plans for centralized companion diagnostics.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Enterprise
Oct 16 BOC Group Adds AI Assistant to ADOIT 21 Oct 16 Huawei Brings Upgraded Stellar Network Solution to Europe Oct 16 Element to Manage Waymo's Toronto Fleet for 2028 Launch Oct 16 CTM and Huawei Plan AI Network Security Upgrades in Macao Oct 16 Huawei and 14 partners form Global AI CITY allianceMore from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Cellular Intelligence Adds Yann LeCun and Three Scientists to Advisory Board
Deep Longevity to Launch Accrua Telehealth Platform in US
Taiwanese Health Technology Groups Test US Market in Dallas
Araceli Adds Cellular Imaging to Ginkgo's Nebula Lab
Basecamp Research Raises $140 Million for AI Designed Therapeutics
Daily AI Brief: the AI news that matters, in your inbox.